PRLD insider buying and SEC filings, explained
Prelude Therapeutics Inc · CIK 1678660
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Apr 21, 2026 | Other purchase | David P Bonita (Director and 10% owner) bought 2,815,315 Common Stock indirectly at $4.44 ($12.5M) in a public offering. New position of 1,126,126 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 23, 2026 |
| Apr 21, 2026 | Other purchase | ORBIMED ADVISORS LLC (Director and 10% owner) bought 2,815,315 Common Stock indirectly at $4.44 ($12.5M) in a public offering. New position of 1,126,126 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Apr 23, 2026 |
| Apr 21, 2026 | Other purchase | Julian Baker (Director and 10% owner) bought 2,252,252 Warrants to purchase Common Stock indirectly at $4.44 ($10.0M) in a public offering. Indirect holdings up 13% to 20,105,994 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 5 other reporting owners. | SEC filing Filed Apr 22, 2026 |
13 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PRLD in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.